	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS	12M IR
Total Revenue	708	660	829	872	926	1,014	1,296	1,590	1,507	1,720	1,943	2,023	1,785	1,860	1,713	1,735
Cost of Operating Revenue	369	320	443	505	550	597	806	974	884	1,022	1,129	1,251	982	1,010	926	925
Gross Profit	338	340	386	367	376	417	490	616	623	699	814	772	803	850	787	810
Gross Margin	47.8	51.6	46.6	42.1	40.6	41.1	37.8	38.7	41.3	40.6	41.9	38.1	45.0	45.7	46.0	46.7
Total Operating Expenses	564	525	691	752	810	881	1,135	1,379	1,316	1,483	1,697	1,874	1,635	1,666	1,656	1,670
Operating Profit	144	136	138	120	116	132	161	210	191	238	245	149	150	194	57	65
Operating Margin	20.4	20.6	16.7	13.7	12.5	13.1	12.4	13.2	12.7	13.8	12.6	7.4	8.4	10.4	3.3	3.8
Financing Income/(Expense) - Net	-72	-59	-73	-60	-63	-47	-49	-60	-49	-32	-27	-43	-54	-70	-62	-60
Profit before Taxes	51	33	98	60	53	80	111	149	127	206	219	105	96	124	-78	-58
Income Taxes	5	8	34	19	12	13	34	46	42	73	58	27	26	33	-30	-24
Profit after Tax	46	25	64	40	41	68	77	103	84	133	160	78	70	91	-49	-34
PAT Margin	6.5	3.8	7.7	4.6	4.5	6.7	6.0	6.5	5.6	7.7	8.3	3.9	3.9	4.9	-2.8	-1.9
EPS - Basic - ex Extraordinary Items	3.73	2.05	5.16	3.28	3.34	5.49	6.26	8.36	6.85	10.80	13.02	6.36	5.64	7.36	-3.96	-2.74
EPS - Diluted - ex Extraordinary Items	3.73	2.05	5.16	3.28	3.34	5.49	6.26	8.36	6.85	10.80	13.02	6.36	5.64	7.36	-3.96	-2.74
EBIT	144	136	138	120	116	132	161	210	191	238	245	149	150	194	57	65
EBITDA	190	186	194	184	183	202	246	303	273	323	341	258	267	328	220	232
EBITDA Margin	26.9	28.1	23.4	21.1	19.8	19.9	19.0	19.1	18.1	18.8	17.5	12.7	15.0	17.7	12.9	13.4

Balance Sheet

Abridged

Understanding Balance Sheet

Hikal Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	358	409	495	501	558	577	690	830	775	879	964	939	967	995	884
Long-Term Investments	3	3	3	3	4	8	3	5	1	5	15	24	6	10	31
Property Plant & Equipment - Net	715	709	705	701	689	730	746	783	885	957	1,164	1,350	1,475	1,478	1,422
Total Non-Current Assets	773	782	775	791	763	803	852	855	993	1,035	1,249	1,446	1,521	1,534	1,481
Total Assets	1,132	1,191	1,270	1,292	1,321	1,379	1,542	1,686	1,768	1,913	2,213	2,385	2,487	2,529	2,365
Total Current Liabilities	449	504	487	536	471	441	560	603	596	657	769	662	757	790	679
Long Term Debt	246	220	255	201	288	320	297	298	304	263	287	490	425	370	376
Total Non-Current Liabilities	252	237	278	224	296	333	312	327	355	323	376	590	543	477	488
Total Liabilities	701	741	765	760	767	774	872	929	951	980	1,145	1,252	1,299	1,267	1,167
Total Shareholders' Equity	431	450	505	532	554	605	669	756	817	933	1,068	1,133	1,188	1,262	1,199
Total Equity	431	450	505	532	554	605	669	756	817	933	1,068	1,133	1,188	1,262	1,199
Total Liabilities & Equity	1,132	1,191	1,270	1,292	1,321	1,379	1,542	1,686	1,768	1,913	2,213	2,385	2,487	2,529	2,365

Cash Flow

Abridged

Understanding Cash Flow Statement

Hikal Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	87.28	74.87	116.49	118.81	108.05	136.99	172.17	219.35	188.89	240.86	231.85	177.09	163.59	234.80	120.40
Working Capital - Increase/(Decrease)	-1.32	-72.02	-35.96	-71.33	11.35	-23.92	-87.16	-89.69	46.49	-57.89	18.70	75.63	-53.32	-28.70	116.90
Net CF from Operating Activities	85.96	2.85	80.53	47.49	119.39	113.07	85.01	129.66	235.38	182.97	250.55	252.72	110.26	206.10	237.30
Capital Expenditures - Net	53.51	26.91	51.24	48.55	58.84	105.25	105.98	128.12	158.00	157.60	273.04	302.05	203.99	136.40	148.00
Net CF from Investing Activities	-53.51	-26.91	-18.19	-48.55	-58.84	-105.25	-105.98	-127.05	-166.31	-158.93	-286.06	-294.24	-175.68	-137.20	-146.40
Dividends Paid - Cash - Total	11.46	11.46	8.66	4.81	9.89	15.83	12.86	16.35	23.78	14.82	27.13	12.33	14.83	14.80	12.30
Debt - LT & ST - Issuance/(Retirement) - Total	-25.18	41.54	-40.66	-3.98	-52.60	5.65	37.73	19.33	-25.02	-33.26	66.44	69.14	66.22	-53.50	-82.00
Net Cash Flow from Financing Activities	-36.64	30.07	-55.23	-8.47	-62.49	-10.18	24.87	2.98	-48.80	-48.08	39.32	56.81	51.39	-68.30	-94.30
Free Cash Flow to Equity	7.27	17.48	-11.37	-5.04	7.96	13.46	16.76	20.87	52.37	-7.90	43.95	19.81	-27.51	16.20	7.30
Free Operating CF net dividend	20.97	-35.53	20.46	-5.87	50.66	-24.87	-33.83	-15.12	53.57	10.55	-49.89	-62.23	-108.76	54.00	76.90
Free Operating CF	32.43	-24.07	29.11	-1.06	60.55	-9.04	-20.97	1.23	77.35	25.37	-22.76	-49.90	-93.93	68.80	89.20

Business Segment Analysis

FY End:

Mar 25

Hikal Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceutical (70.4%)₹ 95.70 CrCrop Protection (27.8%)₹ 37.80 CrUnallocated (1.8%)₹ 2.50 Cr

Revenue / Sales

Pharmaceutical (62.8%)₹ 1,168.10 CrCrop Protection (37.2%)₹ 691.70 Cr

Assets

Pharmaceutical (60.9%)₹ 1,539.30 CrCrop Protection (37.0%)₹ 934.90 CrUnallocated (2.2%)₹ 54.70 Cr

Regional Segment Analysis

FY End:

Mar 25

Hikal Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (37.9%)₹ 704.10 CrEurope (28.5%)₹ 530.00 CrSouth East Asia (16.1%)₹ 299.00 CrU.S.A & Canada (13.5%)₹ 250.60 CrOthers (4.1%)₹ 76.10 Cr

Assets

India (100.0%)₹ 2,528.90 Cr

Historical Segment Analysis

Track how Hikal Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2010 Mar 31	2011 Mar 31	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31
	2010 Mar 31	2011 Mar 31	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31
Pharmaceutical	32	55	63	36	33	53	36	87	80	74	101	92	134	140	139	96
Crop Protection	17	15	6	9	12	11	17	45	38	56	73	54	152	153	93	38
Unallocated	4	3	6	0	7	0	3	3	10	9	13	10	17	5	10	3
Others	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

What is the revenue of Hikal Ltd.?

The latest trailing twelve month revenue of Hikal Ltd. is ₹ 1,735.00 Cr, reflecting a 1-year growth of -5.37% and a 3-year CAGR of -5.14%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Hikal Ltd.?

The latest trailing twelve month net profit (PAT) of Hikal Ltd. is ₹ -42.70 Cr, with a 3-year earnings CAGR of -33.13%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Hikal Ltd.?

The trailing twelve month EBITDA of Hikal Ltd. is approximately ₹ 57.34 Cr (based on an operating margin of 3.30%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Hikal Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Hikal Ltd. is -2.74. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Hikal Ltd.?

The debt-to-equity ratio of Hikal Ltd. stands at 0.57. The interest coverage ratio is 1.24x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Hikal Ltd.?

The estimated book value per share of Hikal Ltd. is 95.55 (derived from a P/B ratio of 2.22 and market price of ₹ 211.90), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Hikal Ltd.?

The trailing twelve month operating cash flow of Hikal Ltd. is ₹ 237.30 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Hikal Ltd. report consolidated or standalone financials?

Hikal Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.